Type 2 Diabetes Medications That Induce Weight Loss
Mar 22, 2024 · Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. A predominant risk factor for type 2 diabetes is being overweight or obese, so weight loss goals while maintaining normal blood sugar levels are very important for some patients.
History of National Diabetes Month 2024
Oct 30, 2024 · November is National Diabetes Month, dedicated to increasing awareness and education on how diabetes affects the body and how it can be prevented.
Gender-Affirming Surgery Rare Among Transgender Children in US
Aug 2, 2024 · Among children and adolescents, 16.8% were aged 15 to 17 years, 11.9% were aged 13 to 14 years, and 71.3% were aged 12 years and younger. The rate of gender-affirming surgery among TGD individuals was 5.3 per 100,000 adults, 2.1 per 100,000 adolescents aged 15 to 17 years, 0.1 per 100,000 adolescents aged 13 to 14 years, and 0 among children aged 12 years and younger.
The 2024 Update to the American Diabetes Association Standards …
Jan 12, 2024 · The American Diabetes Association (ADA) has updated its guidelines for the “Standards of Care” for patients with diabetes. The report has been published in Diabetes Care.. In the 2024 update, the ADA focused on patient-centered care, person-first language, and updated screening and treatment approaches based on the latest clinical evidence.
Diabetes and Erectile Dysfunction - Endocrinology Advisor
Nov 29, 2024 · Erectile dysfunction is a persistent pattern of being unable to attain and/or maintain a penile erection sufficient for sexual satisfaction. 1 It is a common problem, affecting approximately 30 million men in the United States. 1 Compared to those without diabetes, men with diabetes have an increased risk of developing erectile dysfunction. 2 This article describes how diabetes contributes to ...
SGLT2 Inhibitors - Endocrinology Advisor
Oct 9, 2024 · UGT = UDP-glucuronosyltransferase. From the FDA-approved prescribing information for each medication. 5-9 Warnings and Adverse Reactions. All SGLT2 inhibitors are contraindicated for patients who have hypersensitive reactions to SGLT2 inhibitor treatment. 5-9 Bexagliflozin, canagliflozin, and empagliflozin are not recommended for improving glycemic control in patients with type 2 diabetes who ...
How Do GLP-1 Receptor Agonists, Like Ozempic or Mounjaro, Work?
Jun 14, 2024 · Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. Glucagon-like peptide-1 (GLP-1) is a hormone released when food is eaten to slow gastric emptying, the process by which food leaves the stomach, so that the body can absorb nutrients from food.
Addison's Disease - Endocrinology Advisor
Apr 2, 2024 · Addison’s disease — also referred to as primary adrenal insufficiency — occurs when the adrenal glands do not produce enough cortisol and/or aldosterone, hormones necessary for regulation of metabolism, blood pressure, immune system functions, the stress response, and other essential physiologic activities. 1 Patients with Addison’s disease experience weakness, fatigue, anorexia ...
GLP-1 Agonists - Endocrinology Advisor
Oct 8, 2024 · Glucagon-like peptide-1 receptor agonists (GLP-1 agonists) are a newer class of medications that are US Food and Drug Administration (FDA)-approved to manage type 2 diabetes and obesity in conjunction with diet and lifestyle changes. 1 GLP-1 agonists affect glycemic control and body weight by increasing insulin production and release in a glucose-dependent manner; decreasing glucagon secretion ...
Sellar Mass - Endocrinology Advisor
Dec 7, 2022 · History & Epidemiology. Sellar masses (SMs) are adenoma bodies that are typically located on or around the pituitary gland, specifically near the sella turcica. 1,2 Sellar masses are known to account for approximately 10% to 15% of all intracranial neoplasms. 3,4 and are responsible for a myriad of visual, neurological, and hormonal deficiencies. 3 Pituitary adenomas (PAs) account for the vast ...